LobbyingBiocom lobbying by quarter
Biocom's latest lobbying report covers Q2 2026, at $75K. The four quarters Q4 2025–Q3 2026 total $225K. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Copyright/Patent/Trademark.
Biocom
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $225K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $75K | 1 |
| Q1 2023 | $75K | 1 |
| Q2 2023 | $75K | 1 |
| Q3 2023 | $75K | 1 |
| Q4 2023 | $75K | 1 |
| Q1 2024 | $75K | 1 |
| Q2 2024 | $75K | 1 |
| Q3 2024 | $75K | 1 |
| Q4 2024 | $75K | 1 |
| Q1 2025 | $75K | 1 |
| Q2 2025 | $75K | 1 |
| Q3 2025 | $75K | 1 |
| Q4 2025 | $75K | 1 |
| Q1 2026 | $75K | 1 |
| Q2 2026 | $75K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$202.5K · 15 reports
- Copyright, patent and trademark$202.5K · 15 reports
- Health issues$202.5K · 15 reports
- Trade$202.5K · 15 reports
- Taxation$157.5K · 12 reports
- Agriculture$87.5K · 7 reports
- Economic development$70K · 5 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Patent & Trademark Office (PTO)7 reports
- Food & Drug Administration (FDA)5 reports
- Office of Science & Technology Policy (OSTP)3 reports
- Commerce, Dept of (DOC)2 reports
- Agriculture, Dept of (USDA)1 reports
- Environmental Protection Agency (EPA)1 reports
- Government Accountability Office (GAO)1 reports
- Health & Human Services, Dept of (HHS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseBiocom | $1.1M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/03for Q2 | In-house | $75K |
| 04/17for Q1 | In-house | $75K |
| 01/15for Q4 2025 | In-house | $75K |
| 25/10/13for Q3 2025 | In-house | $75K |
| 25/07/15for Q2 2025 | In-house | $75K |
| 25/06/13for Q1 2025 | In-house | $75K |
| 25/06/13for Q1 2025 | In-house | $75K |
| 25/01/21for Q4 2024 | In-house | $75K |
| 24/10/22for Q3 2024 | In-house | $75K |
| 24/07/22for Q2 2024 | In-house | $75K |
| 24/04/22for Q1 2024 | In-house | $75K |
| 24/01/22for Q4 2023 | In-house | $75K |
| 23/10/20for Q3 2023 | In-house | $75K |
| 23/07/18for Q2 2023 | In-house | $75K |
| 23/04/20for Q1 2023 | In-house | $75K |
| 23/01/20for Q4 2022 | In-house | $75K |